Een aloud gezegd luidt: De kost gaat voor de baat. Dat Kiadis meer geld heeft gebruikt is niet vreemd gezien het volgende uit de rapportage van 30 april 2019:
The global phase 3 trial for ATIR101, CR-AIR-009, is ongoing. The study, which will enroll approximately 250 patients, is comparing ATIR101 to the post-transplant cyclophosphamide (PTCy) or 'Baltimore' protocol.
Additionally, over the past year
- the organization has been strengthened across all functions, with the addition of more than 60 staff, including key management team members.
- On April 17, 2019, Kiadis announced that it had entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc., subject to shareholder approval and customary closing conditions. The combination of Kiadis and CytoSen will create a leader in cell-based cancer immunotherapy, with complementary T-Cell and NK-cell platforms.
- This increase was primarily caused by a further expansion of the workforce in all areas of the organization, clinical expenses related to the CR-AIR-009 study,
- the move to a larger building which includes a commercial manufacturing facility, laboratories and office space.
- General and Administrative expenses increased to EUR 7.7 million in 2018 from EUR 4.9 million in 2017. Without the expenses for share-based compensation, General and Administrative expenses were EUR 3.0 million higher at EUR 7.0 million in 2018 compared to EUR 4.0 million in 2017. The increase was due to the expansion of the workforce, higher consultancy expenses related to market access preparations and financing rounds.